CompletedPhase 2NCT04154293
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
Studying Autosomal recessive congenital ichthyosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Timber Pharmaceuticals Inc.
- Principal Investigator
- Alan M Mendelsohn, MD, MDTimber Pharmaceuticals
- Intervention
- Isotretinoin(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 9 years · All sexes
- Timeline
- 2019 – 2021
Study locations (11)
- Medical Dermatology Specialists, Phoenix, Arizona, United States
- Stanford University School of Medicine, Palo Alto, California, United States
- Yale Center for Clinical Investigation, New Haven, Connecticut, United States
- The Indiana Clinical Trials Center, Plainfield, Indiana, United States
- Austin Institute for Clinical Research, Inc, Metairie, Louisiana, United States
- Minnesota Clinical Study Center, New Brighton, Minnesota, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Queensland Children's Hospital, Brisbane, Queensland, Australia
- Premier Specialists, The church, Kogarah, Sydney, Australia
- Murdoch Children's Research Institute, RCH, Melbourne, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04154293 on ClinicalTrials.gov